A Mendelian randomization study provided evidence that genetic predisposition to elevated levels of inflammatory cytokines, such as IL-17, is linked to both psoriasis and systemic inflammation, supporting the need for integrated therapeutic approaches [9]. The gene discussed is IL17A; the disease is psoriasis.